Why the study?
Does acute treatment with TMAO increase myocardial contractile force in ex vivo murine and human cardiac tissue?
Does acute treatment with TMAO increase myocardial contractile force in ex vivo murine and human cardiac tissue?
TMAO acutely and directly increases cardiac muscle contractility by augmenting cytosolic calcium, providing mechanistic insight into cardiovascular pathogenesis in CKD.
Hypothesis-generating for TMAO effects on contractility; leaves open in vivo relevance and clinical implications.
We demonstrate for the first time that elevated concentrations of TMAO acutely augment myocardial contractile force ex vivo in both murine and human cardiac tissue. To gain mechanistic insight into the processes that led to this potentiation in cardiac contraction, we used two-photon microscopy to evaluate intracellular calcium in ex vivo whole hearts loaded with the calcium indicator dye Fluo-4. Acute treatment with TMAO resulted in increased Fluo-4 fluorescence, indicating that augmented cytosolic calcium plays a role in the effects of TMAO on force production. Lastly, TMAO did not show an effect on aortic smooth muscle contraction or relaxation properties. Our results demonstrate novel, acute, and direct actions of TMAO on cardiac function and help lay the groundwork for future translational studies investigating the complex multiorgan interplay involved in cardiovascular pathogenesis during CKD.
No takes yet. Share an insight, caveat, or question.
Oakley et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: